Stephen Harrison, MD
Gastroenterology · Live Oak, TXNPI 1104805506
Payments from drug & device makers
Across 495 payments — averaging $10,625 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$1.1M
- Genentech, Inc.$884K
- Intercept Pharmaceuticals, Inc.$544K
- Boehringer Ingelheim$523K
- E.r. Squibb & Sons, L.L.C.$476K
- Echosens North America, Inc.$331K
- plus $1.4M from 29 others
Across 4 payments — averaging $91,068 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$364K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 8 | $1,120,212 |
| Genentech, Inc. | 69 | $884,285 |
| Intercept Pharmaceuticals, Inc. | 84 | $544,235 |
| Boehringer Ingelheim | 7 | $522,994 |
| E.r. Squibb & Sons, L.L.C. | 11 | $476,223 |
| Echosens North America, Inc. | 36 | $331,405 |
| Perspectum Diagnostics Ltd | 19 | $288,042 |
| Gilead | 51 | $283,974 |
| Amgen | 2 | $171,163 |
| Provepharm Inc. | 2 | $145,030 |
| Pfizer | 13 | $134,956 |
| Novo Nordisk AS | 49 | $89,712 |
| Braintree Laboratories, Inc. | 33 | $82,237 |
| Corcept Therapeutics | 27 | $74,476 |
| Intercept Pharma Europe Ltd. | 6 | $33,808 |
| Merck | 3 | $19,870 |
| Boehringer Ingelheim RCV GmbH & Co KG | 29 | $15,562 |
| AbbVie(2 entities) | 13 | $13,750 |
| GSK | 7 | $8,661 |
| Theratechnologies Inc. | 2 | $5,900 |
| Dexcom, Inc. | 3 | $4,560 |
| Kowa Research Institute, Inc. | 1 | $3,202 |
| Regeneron | 1 | $1,828 |
| AstraZeneca | 3 | $1,697 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $868 |
| Novartis | 1 | $417 |
| ERBE USA Inc | 1 | $81 |
| Novo Nordisk | 2 | $55 |
| La Jolla Pharmaceutical Company | 1 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| Lilly USA, LLC | 1 | $31 |
| Olympus America Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $14 |
| Ferring Pharmaceuticals Inc. | 1 | $13 |
| Nestle Healthcare Nutrition Inc. | 1 | $13 |
How this compares
$5,259,355 in reported general payments places this provider in the 95th percentile of 1,350 gastroenterology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gastroenterology in Live Oak
- Eric LawitzSan Antonio$59.5M
- George DuvallTyler$17.5M
- John FordtranDallas$9.9M
- Timothy RitterSouthlake$7.7M
- Parvez MantryDallas$6.4M
- Mazen NoureddinHouston$6.1M
- Nadege GunnWaco$5.7M
- Michael BrownDallas$5.5M
- James MaherHouston$5.3M
- Uma MohanHouston$5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.